Drug Profile

Retlirafusp alfa - Jiangsu Hengrui Medicine

Alternative Names: SHR 1701

Latest Information Update: 22 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Developer Atridia; Chinese PLA General Hospital; Fudan University; Jiangsu Hengrui Medicine Co.; Suzhou Suncadia Biopharmaceuticals
Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Transforming growth factor beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Phase III Cervical cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer
Phase II/III Colorectal cancer
Phase II Biliary cancer; HER2 negative breast cancer; Malignant melanoma; Pancreatic cancer; Rectal cancer; Squamous cell cancer
Phase I/II B-cell lymphoma; Solid tumours
No development reported Nasopharyngeal cancer

16 Sep 2025 Jiangsu HengRui Medicine plans a phase II trial for Non-small cell lung cancer (Late stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in Unknown location (Parenteral, Injection) in October 2025 (NCT07175220)
01 Sep 2025 Fudan University plans a phase II CASTLE-ZS-03 trial for Cholangiocarcinoma (Late-stage disease, Combination therapy, Inoperable/unresectable, Metastatic disease, Second-line therapy or greater) in China (IV), in September 2025 (NCT07147088)
25 Apr 2025 Efficacy data from a phase II trial in Biliary tract cancer and Pancreatic cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com